Khasraw, M., Abrey, L. E., Lassman, A. B., Hormigo, A., Nolan, C., Gavrilovic, I. T., … Omuro, A. M. (2010). Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). In Journal of Clinical Oncology (Vol. 28, pp. 2065–2065). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.2065

Khasraw, M., L. E. Abrey, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, I. K. Mellinghoff, A. S. Reiner, L. M. DeAngelis, and A. M. Omuro. “Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).” In Journal of Clinical Oncology, 28:2065–2065. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.2065.

Khasraw M, Abrey LE, Lassman AB, Hormigo A, Nolan C, Gavrilovic IT, et al. Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 2065–2065.

Khasraw, M., et al. “Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 2065–2065. Crossref, doi:10.1200/jco.2010.28.15_suppl.2065.

Khasraw M, Abrey LE, Lassman AB, Hormigo A, Nolan C, Gavrilovic IT, Mellinghoff IK, Reiner AS, DeAngelis LM, Omuro AM. Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 2065–2065.